MR and Interstitial Fluid Pressure Levels Offer Potential Biomarker for Tumor Aggressiveness

Researchers have validated a noninvasive imaging modality that provides valuable data about interstitial fluid pressure of solid tumors, and may aid in the identification of aggressive tumors.

The study’s findings were published October 2, 2012, in Cancer Research, a journal of the American Association for Cancer Research. Many malignant solid tumors typically develop a higher interstitial fluid pressure (IFP) than healthy tissue. High IFP in tumors may cause a reduced uptake of chemotherapeutic agents and resistance to radiatiotherpay. Moreover, a high IFP has been found to promote metastasis.

“Currently, an imaging method for noninvasive assessment of the IFP of tumors is needed to evaluate the potential of IFP as a biomarker for cancer aggressiveness and, hence, to identify patients with cancer who may benefit from particularly aggressive treatment because of highly elevated tumor IFP,” said Einar K. Rofstad, PhD, of the department of radiation biology at the Institute for Cancer Research, Norwegian Radium Hospital (Oslo, Norway).

Dr. Rofstad and colleagues assessed the use of dynamic contrast-enhanced magnetic resonance imaging (MRI) to evaluate the velocity of fluid flow from tumors in human cell lines of cervical carcinoma and melanoma implanted in laboratory mice. Researchers theorized that the velocity of fluid flow from tumor tissue into neighboring tissue was determined by the IFP drop at the tumor surface.

The findings indicated that the velocity of the fluid flow at the tumor surface strongly correlated with the magnitude of the tumor IFP and that dynamic contrast-enhanced MRI with gadolinium diethylene-triamine penta-acetic acid (Gd-DTPA) as a contrast agent can be used to noninvasively determine the fluid-flow velocity. Furthermore, the lab mice’s primary tumors with metastases had a considerably higher IFP and fluid-flow velocity at the tumor surface compared with the primary tumors of metastasis-free mice, validating that the development of lymph node metastases strongly correlated to the IFP of the primary tumor and the velocity of fluid flow as measured by Gd-DTPA-based dynamic contrast-enhanced MRI.

“Our findings establish that Gd-DTPA-based dynamic contrast-enhanced MRI can noninvasively visualize tumor IFP,” Dr. Rofstad said. “This reveals the potential for the fluid-flow velocity at the tumor surface determined by this imaging method to serve as a novel general biomarker of tumor aggressiveness.”

Dr. Rofstad reported that detailed prospective clinical investigations in several types of cancer are needed to assess the value of fluid-flow velocity at the tumor surface level evaluated by Gd-DTPA-based dynamic contrast-enhanced MRI as a general biomarker for interstitial hypertension-induced cancer aggressiveness.

Related Links:
Institute for Cancer Research, Norwegian Radium Hospital